CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
We describe below transactions and series of similar transactions that we were or will be a party to in which (i) an executive officer,
director, nominee for election as a director, beneficial owner of more than 5% of any class of our Common Stock or any member of the immediate family of any of the foregoing persons and (ii) the amount involved exceeds $120,000.
Other than as described below, there has not been, nor is there any currently proposed, transactions or series of similar transactions to
which we have been or will be a party.
2018 Private Placement Common Stock Financing
On December 19, 2018, we entered into a Securities Purchase Agreement, or the Unit Purchase Agreement, with certain purchasers pursuant to
which we sold and issued 10,272,375 immediately separable units at a price per unit of $1.60625 for aggregate gross proceeds of approximately $16,500,000. Each unit consisted of one share of our Common Stock and a warrant to purchase 0.05 of a share
of our Common Stock at an exercise price of $2.00 per share, for an aggregate of 10,272,375 shares of our Common Stock, or the Shares, and corresponding warrants, or the 2018 PIPE Warrants, to purchase 513,617 shares of our Common Stock, or the
Warrant Shares, referred to collectively as the 2018 Resale Shares. We also granted certain registration rights to the purchasers pursuant to the Unit Purchase Agreement pursuant to which, among other things, we filed a registration statement with
the SEC to register for resale the 2018 Resale Shares in March 2019.
Mr. Sinclair, a member of our Board of Directors, is an
affiliate of Abingworth Bioventures VII L.P., which purchased an aggregate of 4,669,272 shares of Common Stock in the 2018 PIPE Offering (approximately 45.5% of the shares of Common Stock issued in the 2018 PIPE Offering) and warrants to purchase an
aggregate of 233,463 shares of Common Stock (approximately 45.5% of the warrants issued in the 2018 PIPE Offering for an aggregate investment of approximately $7.5 million).
2017 Private Placement Common Stock Financing
On December 11, 2017, we entered into the Unit Purchase Agreement with certain purchasers pursuant to which we sold and issued 8,141,116
immediately separable units at a price per unit of $1.84 for aggregate gross proceeds of approximately $15,000,000. Each unit consisted of one share of our Common Stock and a warrant to purchase 0.74 of a share of our Common Stock at an exercise
price of $2.00 per share, for an aggregate of 8,141,116 Shares and corresponding warrants to purchase 6,024,425 Warrant Shares, together referred to as the 2017 Resale Shares. We also granted certain registration rights to the purchasers pursuant to
the Unit Purchase Agreement pursuant to which, among other things, we filed a registration statement with the SEC to register for resale the 2017 Resale Shares in January 2018.
Dr. Shah, a member of our Board of Directors at the time of the 2017 PIPE Offering, is an affiliate of the entities affiliated with Vivo
Ventures, which purchased an aggregate of 1,085,480 shares of Common Stock in the 2017 PIPE Offering (approximately 13.3% of the shares of Common Stock issued in the 2017 PIPE Offering) and warrants to purchase an aggregate of 803,255 shares of
Common Stock (approximately 13.3% of the warrants issued in the 2017 PIPE Offering for an aggregate investment of approximately $2 million).
Merger with Essentialis, Inc. and Common Stock Financing
On March 7, 2017, we entered into Common Stock purchase agreements, or the Common Stock Purchase Agreements, with certain new and existing
investors who previously delivered
non-binding
indications of interest to us to participate in a financing of up to $8 million in connection with the Merger with Essentialis. Under the terms of the Common
Stock Purchase Agreements, we agreed to sell to the purchasers, in a private placement, an aggregate of 1,666,666 shares of Common Stock, par value $0.001 per share, at a purchase price of $4.80 per
-32-